compound 35 [PMID: 22902653]   

GtoPdb Ligand ID: 8119

Compound class: Synthetic organic
Comment: Compound 35 was designed as an inhibitor of the LIM domain kinases LIMK1 and LIMK2 [2]. Compound 35 exhibits selectivity for the LIMs over the testis-specific protein kinases (TESKs) [2].
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 131.02
Molecular weight 472.03
XLogP 2.01
No. Lipinski's rules broken 0
Canonical SMILES COc1cc(Cl)c(c(c1)Cl)c1cc(nc(n1)c1cnccn1)c1cnc(s1)NC(=O)C
Isomeric SMILES COc1cc(Cl)c(c(c1)Cl)c1cc(nc(n1)c1cnccn1)c1cnc(s1)NC(=O)C
InChI InChI=1S/C20H14Cl2N6O2S/c1-10(29)26-20-25-9-17(31-20)14-7-15(18-12(21)5-11(30-2)6-13(18)22)28-19(27-14)16-8-23-3-4-24-16/h3-9H,1-2H3,(H,25,26,29)
No information available.
Mechanism Of Action and Pharmacodynamic Effects
LIM domain kinases and the related testis-specific protein kinases are known to phosphorylate the actin-binding protein cofilin [1,4,6]. This phosphorylation has an inhibitory effect on cofilin's interaction with F-actin and acts to depolymerise actin, having profound effects on the cytoskeleton [3,5]. LIM kinase inhibitors are being pursued as anti-cancer agents with effects on the invasiveness and metastatic capacity of tumour cells.